# Thijs Cohen Tervaert

> Thijs Cohen Tervaert is a Series A investor at Inkef (Amsterdam) backing Health Care and Biopharma. See 3 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Inkef](https://shizune.co/investors/profile/inkef-capital)
- Location: Amsterdam, The Netherlands
- Total investments: 3
- Last investment: Dec 2025
- Lead investor: 33%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/thijs-cohen-tervaert-5364411

Thijs Cohen Tervaert is a Director at INKEF Capital. He Attended Leiden University.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 2 | 67% |
| Biopharma | 1 | 33% |
| Biotechnology | 1 | 33% |
| Medical Device | 1 | 33% |
| Pharmaceutical | 1 | 33% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 1 | 33% |
| Series B | 1 | 33% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Switzerland | 1 | 33% |
| The Netherlands | 1 | 33% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| TargED Biopharmaceuticals | TargED Biopharmaceuticals is a biotechnology company that develops first-in-class biological drugs to improve treatment of thrombosis.TargED stands for Targeted Enzyme Delivery. Their biological drugs are unique by using small antibodies (“VhH”) to deliver enzymes to sites of thrombosis, enabling ‘targeted’ thrombolysis. | $25.3M | Series A | Dec 16, 2025 |  |
| iOnctura | iOnctura is a biopharmaceutical company focusing on novel therapeutics to modulate key culprits of immunosuppression in the tumor microenvironment. Immune checkpoint inhibitors (eg PD/PD-L1) have shown remarkable effectiveness for some but not for all cancer patients. The company aims to improve current immune checkpoint therapies bydeveloping novel drugs with potential safety and efficacy profiles that when combined with checkpoint inhibition have the potential to optimize clinical outcomes. Through its partnerships with Merck and Cancer Research Technology (the commercial arm of Cancer Research UK, London, UK), iOnctura has established a pipeline of preclinical molecules to advance towards the clinic in combination with immuno-oncology assets from Merck. iOnctura is supported by a world renowned scientific advisory board and, with its access to CRT’s drug discovery labs and network of academic collaborators, is well-positioned to rapidly establish novel combination therapies in the field of cancer immunology. | $85.7M | Series B | Jun 20, 2024 |  |
| TargED Biopharmaceuticals | TargED Biopharmaceuticals is a biotechnology company that develops first-in-class biological drugs to improve treatment of thrombosis.TargED stands for Targeted Enzyme Delivery. Their biological drugs are unique by using small antibodies (“VhH”) to deliver enzymes to sites of thrombosis, enabling ‘targeted’ thrombolysis. | $44.2M | Series A | Feb 19, 2022 |  |

3 of 3 investments shown.

## Co-investors
- [Curie Capital](https://shizune.co/investors/profile/curie-capital) — VC Fund, 2 deals together
- [Andera Partners](https://shizune.co/investors/profile/edmond-de-rothschild-investment-partners) — VC Fund, 2 deals together
- [Fund+](https://shizune.co/investors/profile/fund) — VC Fund, 2 deals together
- [Hadean Ventures](https://shizune.co/investors/profile/hadean-ventures) — VC Fund, 2 deals together
- [Sunstone Life Science Ventures](https://shizune.co/investors/profile/sunstone-capital-life-science) — VC Fund, 2 deals together
- [BioGeneration Ventures](https://shizune.co/investors/profile/biogeneration-ventures) — VC Fund, 1 deal together

## About Inkef

VC Fund · Amsterdam, The Netherlands

Inkef is a venture capital firm based in Amsterdam, backing promising early stage companies in Europe. Inkef takes pride in being a patient, long-term investor with the ability to support companies through several rounds of funding. From the early stages of a technology or life science venture, Inkef supports entrepreneurs building their ideas intosuccessful international businesses.Investment areas: Technology and Healthcare

5 contacts available at Inkef.

| Name | Title | Profile |
| --- | --- | --- |
| Frank Lansink | Partner | https://shizune.co/investors/profile/frank-lansink |
| Thijs Cohen Tervaert | Partner | https://shizune.co/investors/profile/thijs-cohen-tervaert |
| Derk Arts | Founder | https://shizune.co/investors/profile/derk-arts-c179 |
| Ivan Burkov | Principal | https://shizune.co/investors/profile/ivan-burkov |
| Simone Botti | Partner | https://shizune.co/investors/profile/simone-botti |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Thijs Cohen Tervaert invest in?

Thijs Cohen Tervaert invests primarily in Health Care, Biopharma and Biotechnology startups, most often at Series A and Series B stage. Most of the 3 investments tracked by Shizune back companies in Switzerland. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Thijs Cohen Tervaert last invest?

The most recent investment recorded for Thijs Cohen Tervaert closed in Dec 2025. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co